Story perspectives

Pharma Sector Thrives as Pricing Risks Eased

10/15/2025

44 3

Summary

Story summary

The pharmaceutical industry is gaining momentum as tariffs and pricing risks ease.
Johnson & Johnson (J&J) posted 6.8% sales growth to $24 billion and guided for full-year sales of $93.7 billion.
Pfizer Inc.'s pricing deal with the Trump administration reduces sector risk, with Amgen Inc. and AstraZeneca plc following suit.
Johnson & Johnson's chief executive officer expressed optimism about aligning with the administration's drug-pricing and manufacturing goals.

1 of 1

Story summary

The pharmaceutical industry is gaining momentum as tariffs and pricing risks ease.
Johnson & Johnson (J&J) posted 6.8% sales growth to $24 billion and guided for full-year sales of $93.7 billion.
Pfizer Inc.'s pricing deal with the Trump administration reduces sector risk, with Amgen Inc. and AstraZeneca plc following suit.
Johnson & Johnson's chief executive officer expressed optimism about aligning with the administration's drug-pricing and manufacturing goals.